Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong order intake, sales growth, and a strategic focus on North America and international regions, with positive EBITDA margin expectations. The Q&A section highlights strong growth in the sleep business, effective cost mitigation strategies, and positive innovation momentum. Although there are challenges like cost inflation and centralized procurement in China, Philips appears well-positioned to manage these with AI and pricing strategies. Overall, the sentiment is positive, suggesting a potential stock price increase in the near term.
Key Financial Performance
Order intake Grew 6% year-over-year, reflecting continued momentum. Growth was driven by solid performance across Diagnosis & Treatment (D&T) and Connected Care, with North America leading the growth.
Comparable sales Increased by 4% year-over-year, with growth across all business segments, led by Personal Health. Growth was supported by strong consumer sellout and market share gains.
Adjusted EBITDA margin Improved by 40 basis points to 9% year-over-year, despite higher tariffs. Margin expansion was driven by sales growth, favorable mix effects, and productivity measures.
Diagnosis & Treatment (D&T) sales Increased by 2% year-over-year. Image Guided Therapy delivered high single-digit growth, while Precision Diagnosis sales declined in the low single digits due to order book rebuilding and higher exposure to China.
Connected Care sales Increased by 3% year-over-year. Monitoring delivered mid-single-digit growth, driven by higher installations of IntelliVue patient monitors and traction in enterprise monitoring as a service.
Personal Health sales Increased by 9% year-over-year, with double-digit growth in North America and strong contributions from international regions. Growth was supported by demand for innovations like the AI-powered i9000 shaver and Sonicare series.
Free cash flow Improved by EUR 94 million year-over-year, excluding the prior year's U.S. Respironics settlement payout. This was driven by higher earnings, improved working capital, and lower adjusted items.
Net income Rose to EUR 146 million year-over-year, primarily due to higher earnings.
Net debt Reduced to EUR 5.5 billion, with a leverage ratio improvement to 1.8x from 2.2x year-over-year, driven by higher earnings and disciplined capital allocation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Helium-free MRI systems: Philips has installed over 2,200 helium-free MRI systems globally, saving over 6 million liters of helium. They unveiled the industry's first helium-free 3.0T MR systems, expecting regulatory clearance in 2027.
AI-enabled spectral CT: The Verida spectral CT, launched in December 2025, gained traction with initial orders in Europe. It integrates AI for seamless workflow and clinically relevant insights.
AI-powered cardiac MR solution: SmartHeart received FDA clearance, automating complex planning workflows in under 30 seconds, improving productivity and patient experience.
AI-driven interventional platform: Philips is advancing clinical validation for AI and robotics-assisted workflows for minimally invasive treatments, with seven clinical studies underway.
Personal Health innovations: Philips launched the AI-powered Shaver 9000 Prestige Ultra and Sonicare 5700-7300 series, driving sales and market leadership.
North America growth: North America remains a key growth engine, with strong demand across hospital systems and consumer health products.
European market performance: Europe showed stable capital spending and strong demand in several markets, particularly in diagnostic imaging and personal health.
China market dynamics: China's centralized procurement led to longer decision cycles and price-focused environment, impacting equipment demand.
Supply chain optimization: Philips simplified and localized operations, maintaining stable supply chain performance despite Middle East volatility.
Productivity measures: Achieved EUR 126 million in productivity savings in Q1 2026, targeting EUR 1.5 billion over three years.
Quality improvements: Field actions reduced by 20% year-to-date, reflecting enhanced quality processes and regulatory engagement.
Long-term partnerships: Signed a strategic partnership with WellSpan Health in the U.S., expanding Philips' role in imaging and diagnostics.
M&A strategy: Acquired SpectraWAVE to strengthen interventional platform and coronary leadership, with integration progressing well.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Developments in the Middle East: Increased volatility in logistics and input costs, including materials and components, due to geopolitical developments in the Middle East. This could impact supply chain operations and drive cost inflation.
Helium Supply Constraints: Tightening helium supply, exacerbated by geopolitical developments, is increasing costs and testing resilience in MRI systems. This poses challenges for uninterrupted imaging and reliable service.
China Market Dynamics: Centralized procurement in China is driving longer decision cycles and a more price-sensitive environment, leading to lower order conversion and ongoing pressure on equipment demand.
Input Cost Inflation: Rising input costs, including freight, electronic components, plastics, and energy, are creating headwinds. These pressures are expected to impact margins and require active mitigation.
Regulatory and Compliance Risks: Ongoing engagement with global regulatory authorities, including the FDA, underscores the need for continuous quality and compliance improvements. Regulatory hurdles could impact operations and product approvals.
Tariff Impacts: Higher tariffs are affecting costs and margins, with potential for further impact depending on tariff developments and refunds.
Workforce Shortages in North America: Persistent workforce shortages in North America are driving consolidation among larger health systems and increasing demand for productivity-enhancing platforms.
Economic Uncertainty: Uncertain macroeconomic conditions, including geopolitical and economic factors, are creating a volatile operating environment that could impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Guidance: Philips reiterates its full-year guidance for 2026, expecting comparable sales growth of 3% to 4.5%, with growth in each quarter within this range. North America and international regions are expected to lead this growth.
Segment Performance Expectations: Connected Care and Personal Health segments are expected to grow at the upper end of the guidance range, while Diagnosis & Treatment is expected to grow at the lower end.
China Market Outlook: Comparable sales in China are expected to remain stable in 2026, with growth in Personal Health offsetting a slight decline in health systems due to subdued near-term market conditions.
Adjusted EBITDA Margin: The full-year adjusted EBITDA margin is expected to be between 12.5% and 13%, with some near-term margin pressure due to tariffs, inflation, and foreign exchange impacts.
Free Cash Flow: Free cash flow for 2026 is projected to be between EUR 1.3 billion and EUR 1.5 billion.
Tariff and Cost Mitigation: Philips is actively mitigating cost pressures from tariffs, freight, electronic components, and plastics through supply chain optimization, productivity measures, and selective pricing actions.
Innovation and Product Launches: Philips plans to launch the industry's first helium-free 3.0T MR systems in 2027, positioning itself for a fully helium-free MR portfolio. Additionally, AI-driven innovations like SmartHeart and Verida spectral CT are expected to drive growth.
North America Growth: North America is expected to remain a key growth engine in 2026 and over the medium term, driven by stable hospital activity levels and demand for secure, productivity-enhancing platforms.
Macroeconomic and Geopolitical Factors: Developments in the Middle East are expected to impact sales in 2026, though not materially at the group level. Supply chain and logistic constraints are anticipated to drive cost inflation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the building blocks of the mid-single-digit order growth in D&T for the quarter, and how sustainable is the U.S. market strength?
A:The mid-single-digit D&T growth is driven by strong order intake in IGT (high single digits and above), mid-single-digit PD order intake outside China, and increased demand for MR solutions, particularly helium-free MR. The U.S. market remains strong with growing patient volumes and procedures, supported by long-term partnerships with major health systems. Europe is also performing well, while China shows cautious development with differentiated performance by modality.
Q:Can you break down the quarter's EBITA performance across productivity, mix, and innovation, and discuss the sustainability of these factors?
A:The EBITA performance saw a 40 bps expansion in Q1, driven by volume, business mix, and higher gross margins from innovations like CT 5300, point-of-care ultrasound, and MR BlueSeal. Productivity improvements contributed EUR 126 million, offsetting tariff impacts and input cost inflation. The company is leveraging AI, reducing bill of material costs, and selectively increasing prices to sustain margins.
Q:What is Philips' exposure to centralized procurement in China for ultrasound and CT, and how does it impact performance?
A:Centralized procurement in China significantly impacts ultrasound and CT due to pricing pressure, though volumes are holding. IGT and MR are less affected as they are outside centralized procurement. The biggest impact is on PD, with ultrasound and CT facing the most pressure. China contributes 15% of global revenue, with MR being 50% of that and better protected.
Q:How has Philips' sleep business performed outside the U.S., and what is the innovation strategy in this segment?
A:The sleep business outside the U.S. has seen strong double-digit growth, led by Japan and markets where Philips is returning. Innovations like new mask portfolios and software updates are driving growth. The company is also making progress on regulatory mitigation with the FDA.
Q:What is the impact of cost inflation, particularly on memory chips, and how is Philips addressing it?
A:Philips is experiencing cost inflation in freight, electronic components, and plastics, which is included in their guidance. Mitigation actions include reducing bill of material costs, leveraging AI for efficiencies, and selective pricing increases. Tariff tailwinds are also helping offset inflation.
Q:What is the growth profile for Personal Health (PH) in the second half of the year, considering more difficult comps?
A:PH had a strong Q1 with double-digit growth in North America and slightly positive pricing due to innovations like the 9000 shaver and new Sonicare range. The company expects PH to be at the higher end of the 3%-4.5% full-year guidance, supported by expanded retail distribution and strong innovation momentum.
Q:What is Philips' perspective on the impact of a competitor's ownership change in patient monitoring?
A:Philips sees the ownership change of a competitor in patient monitoring as net neutral. The company has strong partnerships and a platform play that resonates well with customers, driving long-term partnerships and share gains in monitoring.
Q:Why does Philips believe it is better positioned to mitigate inflationary headwinds compared to competitors like GE Healthcare?
A:Philips has a strong track record of productivity improvements, selective pricing, and leveraging AI for efficiencies. The company also benefits from tariff tailwinds and has a prudent full-year guidance that accounts for inflationary pressures.
Q:What are the reasons for the low single-digit decline in Enterprise Informatics (EI) sales in Q1, and what is the outlook for the segment?
A:The decline in EI sales is due to the lumpiness of sales, SaaS model transitions, and customer migrations. However, order intake is strong, and the company sees positive trends in integrated diagnostics and cloud migration, supported by partnerships like Amazon.
Q:What are the selective pricing initiatives Philips is implementing, and how quickly will they impact margins?
A:Philips is increasing prices in segments like Image Guided Therapy, hospital patient monitoring, and service contracts. Some pricing impacts will be seen in 2026, while others will take longer to flow through the order book.
Q:What is the competitive outlook for Philips in Europe, particularly in ultrasound and with the launch of Verida?
A:Philips is performing well in Europe, with strong momentum in MR (BlueSeal), ultrasound, and the new Verida launch. Verida has strong clinical support and secured its first order. The company is confident in its AI-based, high-productivity solutions.
Q:How is Philips addressing inflationary pressures in Q2, and what is the margin outlook for the quarter?
A:Philips expects Q2 margins to be lower year-on-year due to incremental tariffs and cost inflation. Mitigation actions, including bill of material reductions and AI-enabled efficiencies, are back-end loaded and expected to improve margins in the second half of the year.
Q:What is Philips' strategy in China, and how does it align with the company's guidance?
A:Philips is focusing on segments where it can differentiate, such as MR (helium-free), IGT, and cardiac ultrasound. The company has exited commoditized and low-price segments like DXR and value play. This selective approach aligns with the company's guidance and derisks its China strategy.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific level of price adjustments linked to centralized procurement in China and the exact impact of inflationary pressures compared to competitors like GE Healthcare. Additionally, there was no clear quantification of the exposure to memory chip cost inflation or the precise contribution of Verida sales in 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Demand
Guided Therapy
Helium
Image Guided
MR system
Middle East
SmartHeart
Sonicare series
allocation
backdrop
blade
clearance
commitment
currency effect
development Middle
device integration
digit strength
discipline
distribution
efficiency
enterprise monitoring
experience
health system
helium MR
industry
inflation currency
input cost
logistics
measure tariff
monitoring service
pillar
pressure
strength North
tariff inflation
technology
uncertainty
workflow
PHG Transcript
Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary indicates strong order intake, sales growth, and a strategic focus on North America and international regions, with positive EBITDA margin expectations. The Q&A section highlights strong growth in the sleep business, effective cost mitigation strategies, and positive innovation momentum. Although there are challenges like cost inflation and centralized procurement in China, Philips appears well-positioned to manage these with AI and pricing strategies. Overall, the sentiment is positive, suggesting a potential stock price increase in the near term.
Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call reflects a mixed outlook: strong order growth and margin improvements indicate potential positives, but uncertainties around tariffs and vague management responses about future challenges temper enthusiasm. The Q&A reveals concerns about flat growth in China and potential headwinds from tariffs. The financial performance and strategic updates are not strong enough to drive a significant stock movement, thus a neutral sentiment is appropriate.
Koninklijke Philips N.V. (PHG) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary indicates strong financial performance with increased EPS, productivity savings, and positive sales growth, particularly in Personal Health. The Q&A section reveals effective strategies for mitigating risks, such as tariff impacts and competition in China. The company's cautious but optimistic outlook, combined with strategic partnerships and ongoing innovations, supports a positive sentiment. Despite some uncertainties, the overall tone is positive, suggesting a likely stock price increase in the short term.
Koninklijke Philips N.V. (PHG) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call presents a mixed outlook. Strong points include growth in Personal Health and order strength in North America. However, uncertainties like tariff impacts, cautious guidance, and vague responses about future margins dampen positivity. The absence of a market cap makes it difficult to predict strong reactions. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
PHG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
